By
Trending Posts
Can Novo Nordisk’s AI Partnership with AWS Transform…
Copenhagen/London, August 2026 — Novo Nordisk and Amazon Web Services (AWS) have entered into a strategic partnership aimed…
OmniAb and Eli Lilly Announce $370M Global Collaboration…
Emeryville, Calif. and Indianapolis, Ind. — August 17, 2026 — OmniAb, Inc. (NASDAQ: OABI), a leading provider of…
Sandoz’s $314M Bet on Chinese Biosimilars Targets a…
Inside the Sandoz-Henlius licensing deal for biosimilars of Repatha, Benlysta, and Erbitux — and why one of the…
Merck and Moderna’s Melanoma Vaccine Win Could Be…
What the Phase 3 intismeran autogene + Keytruda results mean for the next wave of personalized cancer vaccines…
Prosper Medical’s $16M Raise Is a Bet That…
Analysis of Prosper Medical’s seed round, its AI-powered care model, and what it signals about the next phase…
The FDA Just Created a Reimbursement Pathway for…
Analysis of the FDA’s TEMPO pilot, its first AI-enabled participant, and what it signals for how algorithmic health…
GSK Bets on Cambridge: Inside the R&D Push…
A look at GSK’s new Cambridge research centre, its cost-cutting programme, and what a 75% profit drop tells…
Most-Favored-Nation Pricing: How U.S. Drug Prices Are Being…
A quick-read guide to the Trump administration’s MFN pricing policy and what it means for biopharma GLOBAL BIOPHARMA…
Inside Medicare’s First Price Cuts: What a 38–79%…
A data-driven look at the first round of Medicare drug price negotiation, how it compares to the pricing…
Trending Posts
Latest Stories
Can Novo Nordisk’s AI Partnership with AWS Transform the Drug Discovery Timeline?
Copenhagen/London, August 2026 — Novo Nordisk and Amazon Web Services (AWS) have entered into a…
OmniAb and Eli Lilly Announce $370M Global Collaboration to Discover Antibody-Based Therapeutics Targeting Ion Channels
Emeryville, Calif. and Indianapolis, Ind. — August 17, 2026 — OmniAb, Inc. (NASDAQ: OABI), a…
Sandoz’s $314M Bet on Chinese Biosimilars Targets a Drug the Industry Couldn’t Crack for a Decade
Inside the Sandoz-Henlius licensing deal for biosimilars of Repatha, Benlysta, and Erbitux — and why…
Merck and Moderna’s Melanoma Vaccine Win Could Be the Proof Point mRNA Oncology Has Been Waiting For
What the Phase 3 intismeran autogene + Keytruda results mean for the next wave of…
Gallery
